BPT Crunch

Companies on the Cutting Edge of Healthcare Innovations

back to Marketplace

Veralox Therapeutics

Veralox Therapeutics logo

Founded
2017
Geography
United States of America based
Funding
$22 M

Veralox Therapeutics develops small molecule therapeutics that treat the underlying pathologies of thrombosis and type 1 diabetes. Based on an understanding of the molecular mechanisms of these diseases, these efforts will lead to new treatment paradigms and better outcomes for patients.


diabetes

Technologies

AI Companies (Drug Discovery)   Pharmaceutical and Drug Discovery  

R&D Platform

12-lipoxygenase (12-LOX) is an enzyme in the arachidonic acid (AA) pathway that oxidizes AA resulting in the production of 12-HETE. High 12-LOX activity and 12-HETE production have been linked to numerous syndromes and diseases, with elevated levels of serum 12-HETE having potential implications as a predictive biomarker for T1D.


Pipelines

No pipelines published yet

Products

 

Services

No services posted yet